文献速递心血管CT

CT衍生细胞外容积对低流速低梯度主动脉瓣狭窄TAVR患者的预后价值

Prognostic Value of Computed Tomography-Derived Extracellular Volume in TAVR Patients With Low-Flow Low-Gradient Aortic Stenosis.
PubMed 文献 · JACC Cardiovasc Imaging · 2020-10-28

研究纳入150例接受TAVR的低流速低梯度主动脉瓣狭窄患者,用术前CTA定量细胞外容积(ECV)。中位随访13.9个月,31例(21%)发生死亡+心力衰竭再住院;ECV每增加1%,死亡+HFH风险HR 1.04(95%CI 1.01–1.09;p<0.01)。作者认为CTA测量的ECV升高可能与TAVR后不良临床结局风险增加相关,可能作为无创预后标志物。

要点

  • 低流速低梯度主动脉瓣狭窄TAVR患者中,术前CTA测量的ECV升高与死亡+HFH风险增加相关(HR 1.04/1%,95%CI 1.01–1.09)。
  • 发生死亡+HFH者ECV均值35.5±9.6%,未发生者为29.9±8.2%(p<0.01)。
  • ECV可在术前CTA上测量,作为心肌纤维化的无创标志物用于TAVR预后评估。

核心结论

  • 在低流速低梯度主动脉瓣狭窄患者中,CTA测量的ECV升高与TAVR后不良临床结局风险增加相关,可能作为有用的无创预后标志物。

研究设计与样本

  • 研究类型为在150例接受TAVR的低流速低梯度主动脉瓣狭窄患者中评估术前CTA测量ECV与临床结局关联的研究。
  • ECV使用术前TAVR的CTA定量;参考标准为电子病历中的超声心动图与临床信息,包括全因死亡和心力衰竭再住院(HFH)。
  • 采用Cox比例风险模型评估ECV与死亡+HFH的关联。

诊断标准与关键数值

  • ECV每增加1%,死亡+HFH风险HR 1.04(95%CI 1.01–1.09;p<0.01)。
  • 发生死亡+HFH者ECV均值35.5±9.6%,未发生者29.9±8.2%(p<0.01)。
  • 发生死亡+HFH者STS评分中位数9.9 vs 未发生者4.7(p<0.01)。
  • 发生死亡+HFH者左心室射血分数42.3±20.2% vs 未发生者52.7±17.2%(p<0.01)。
  • 发生死亡+HFH者平均跨瓣压差24.9±8.9 mm Hg vs 未发生者28.1±7.3 mm Hg(p=0.04)。

临床应用与阅片要点

  • 在低流速低梯度主动脉瓣狭窄TAVR术前CTA中可定量ECV,用于辅助预后评估。
  • ECV升高可能与TAVR后死亡+HFH风险增加相关,阅片时可结合ECV数值进行风险分层参考。
  • 作者认为CTA测量的ECV可能作为无创预后标志物,原文未据此给出具体推荐等级。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The association between extracellular volume (ECV) measured by computed tomography angiography (CTA) and clinical outcomes was evaluated in low-flow low-gradient (LFLG) aortic stenosis (AS) patients undergoing transcatheter aortic valve replacement (TAVR).

BACKGROUND: Patients with LFLG AS comprise a high-risk group with respect to clinical outcomes. Although ECV, a marker of myocardial fibrosis, is traditionally measured with cardiac magnetic resonance, it can also be measured using cardiac CTA. The authors hypothesized that in LFLG AS, increased ECV may be associated with adverse clinical outcomes.

METHODS: In 150 LFLG patients with AS who underwent TAVR, ECV was quantified using pre-TAVR CTA. Echocardiographic and clinical information including all-cause death and heart failure rehospitalization (HFH) was obtained from electronic medical records. A Cox proportional hazards model was used to evaluate the association between ECV and death+HFH.

RESULTS: During a median follow-up of 13.9 months (range 0.07 to 28.9 months), there were 31 death+HFH events (21%). Patients who experienced death+HFH had a greater median Society of Thoracic Surgery score (9.9 vs. 4.7; p < 0.01), lower left ventricular ejection fraction (42.3 ± 20.2% vs. 52.7 ± 17.2%; p < 0.01), lower mean transvalvular gradient (24.9 ± 8.9 mm Hg vs. 28.1 ± 7.3 mm Hg; p = 0.04) and increased mean ECV (35.5 ± 9.6% vs. 29.9 ± 8.2%; p < 0.01) compared with patients who did not experience death+HFH. In a multivariable Cox proportional hazards model, increase in ECV was associated with increase in death+HFH, (hazard ratio per 1% increase: 1.04, 95% confidence interval: 1.01 to 1.09; p < 0.01).

CONCLUSIONS: In patients with LFLG AS, CTA measured increase in ECV is associated with increased risk of adverse clinical outcomes post-TAVR and may thus serve as a useful noninvasive marker for prognostication.

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Tamarappoo B, Han D, Tyler J, et al. Prognostic Value of Computed Tomography-Derived Extracellular Volume in TAVR Patients With Low-Flow Low-Gradient Aortic Stenosis. JACC Cardiovasc Imaging. 2020. PMID: 33129731. doi:10.1016/j.jcmg.2020.07.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。